Zentalis Pharmaceuticals (ZNTL) announced the FDA has lifted the partial clinical hold on studies of azenosertib, the company's selective, and orally bioavailable inhibitor of WEE. The FDA has cleared the company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan.
Zentalis said it will be working with clinical trial investigators to resume study activities across the azenosertib development program. The company remains on track to meet all previously disclosed data guidance for the remainder of 2024.
Shares of Zentalis Pharmaceuticals are up 35% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.